UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13A-16 or 15d-16 of

The Securities Exchange Act of 1934

 

For the month of May 2020

 

COMMISSION FILE Number. 000-29338

 

CORREVIO PHARMA CORP.

 

(Translation of registrant’s name into English)

 

1441 Creekside Drive, 6th floor

Vancouver, British Columbia, V6J 4S7, CANADA

 

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

  

 

 

 
 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit   Description
     
99.1   News Release dated May 15, 2020 - CORREVIO ANNOUNCES RESULTS FROM ANNUAL GENERAL AND SPECIAL MEETING OF SECURITYHOLDERS
99.2   Report of Voting Results

  

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CORREVIO PHARMA CORP.
  (Registrant)
     
Date: May 15, 2020 By: /s/ Justin Renz
    Name: Justin Renz
    Title: President and Chief Financial Officer

 

 

 


Correvio Pharma (NASDAQ:CORV)
過去 株価チャート
から 5 2024 まで 6 2024 Correvio Pharmaのチャートをもっと見るにはこちらをクリック
Correvio Pharma (NASDAQ:CORV)
過去 株価チャート
から 6 2023 まで 6 2024 Correvio Pharmaのチャートをもっと見るにはこちらをクリック